Kidney disease-focused primary-outcome trials with sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and non-steroidal mineralocorticoid receptor antagonists. Here, SLC5A2 is linked to kidney disorder.